Dealmaking for Life Sciences Issuers in the COVID-19 World
May
12
2020
Date: May 12, 2020
Time: 1:00PM - 2:00PM (EST)
Location: View the Webinar Recording
The COVID-19 global pandemic has fundamentally altered how equity financing and M&A transactions are being structured by and for life sciences issuers.
Join this panel of life sciences industry experts, from investment bankers and advisers to equity capital market participants and companies exploring M&A transactions, to learn about what trends and opportunities they see as the “new normal” continues to evolve.
Speakers
Moderator
John T. Rudy
Panelist
John T. Rudy is a Mintz Member who represents clients in capital markets transactions, securities, equity debt financings, and mergers and acquisitions. John's clients include public and private companies and investment banks. Before joining Mintz, he was an associate in a New York law firm.
Marc D. Mantell
Panelist
Marc D. Mantell handles corporate and securities law matters at Mintz, primarily for technology clients. He represents companies, investors, underwriters, and other parties in mergers and acquisitions, securities offerings, debt financings, and other transactions.
Helen Cheng
Panelist
Managing Director, Houlihan Lokey
Ben Conway
Panelist
Managing Director, Consilium Partners
Eugene Rozelman
Panelist
Managing Director, Head of Biotechnology & Specialty Pharmaceuticals (US), Canaccord Genuity